USPTO serial 77179357
Reviewed by CopyMark Law Group
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
AMSTERDAM MOLECULAR THERAPEUTICS (AMT) IP B.V.
AMSTERDAM, NL
Other trademarks owned by AMSTERDAM MOLECULAR THERAPEUTICS (AMT) IP B.V.
AMSTERDAM MOLECULAR THERAPEUTICS (AMT) HOLDING N.V.
AMSTERDAM, NL
Other trademarks owned by AMSTERDAM MOLECULAR THERAPEUTICS (AMT) HOLDING N.V.
AMSTERDAM MOLECULAR THERAPEUTICS (AMT) HOLDING N.V.
AMSTERDAM, NL
Other trademarks owned by AMSTERDAM MOLECULAR THERAPEUTICS (AMT) HOLDING N.V.
Amsterdam Molecular Therapeutics (AMT) B.V.
Amsterdam, NL
Other trademarks owned by Amsterdam Molecular Therapeutics (AMT) B.V.
Amsterdam Molecular Therapeutics (AMT) B.V.
Amsterdam, NL
Other trademarks owned by Amsterdam Molecular Therapeutics (AMT) B.V.
Amsterdam Molecular Therapeutics (AMT) B.V.
Amsterdam, NL
Other trademarks owned by Amsterdam Molecular Therapeutics (AMT) B.V.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer Lee Taylor
JENNIFER LEE TAYLOR MORRISON & FOERSTER LLP425 MARKET STREETSAN FRANCISCO, CA 94105-2482UNITED STATES| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological preparations for use in medical and clinical gene therapy and cell therapy; clinical medical reagents for use in gene therapy, gene diagnosis, and gene testing; pharmaceutical preparations, namely, vaccines for use in gene therapy; gene therapy and prophylaxis products, namely, gene delivery, gene transfer, gene regulation and gene modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, cancer, inflammatory and auto-immune diseases, vascular disorders, and single gene disorders | SECTION 8 - CANCELLED | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 10, 2016 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Sep 14, 2011 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Nov 25, 2009 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Nov 18, 2009 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Nov 3, 2009 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 30, 2009 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Sep 30, 2009 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Apr 21, 2009 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 27, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 7, 2009 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 24, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 22, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 21, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 21, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 21, 2008 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Nov 14, 2008 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Oct 22, 2008 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Apr 22, 2008 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Apr 22, 2008 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 17, 2008 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Apr 17, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 17, 2008 | ALIE | ASSIGNED TO LIE | — |
| Apr 16, 2008 | PAPER RECEIVED | — | |
| Mar 4, 2008 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 27, 2007 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Nov 27, 2007 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Nov 6, 2007 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 6, 2007 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 6, 2007 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 28, 2007 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 27, 2007 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 23, 2007 | DOCK | ASSIGNED TO EXAMINER | — |
| May 17, 2007 | NWAP | NEW APPLICATION ENTERED | — |